

2017 Antibiogram Inpatient Providers (January-December)

Relative Cost Per Day PO/IV ¹	\$\$\$	\$	\$	\$	\$	\$	\$	\$	\$\$\$	\$\$\$	\$	\$\$\$	\$\$\$	\$\$\$ IV	\$	\$
Gram Negative Organisms Legend: • Susceptible Reported as % • (Maximum # strains tested) ↑ > 5% increase in Susceptibility from Previous Year ↓ > 5% decrease in Susceptibility from Previous Year	Amikacin	Ampicillin	Amp/sulbactam	Cefazolin ³	Cefoxitin	Ceftazidime	Ceftriaxone	Ciprofloxacin	Gentamicin	Meropenem	Levofloxacin	Pip/Tazobactam	Tobramycin	Trimethoprim/sulfa	Nitrofurantoin Urinary Tract Infections only	Cefepime ⁴
<i>Escherichia coli</i> (1761)	100	61	67	92 ³ ↑	92	97	94	84↑	94	100	84↑	98	94	83	95	28/74 ^{2,7}
<i>Enterobacter species</i> ² (121)	100	-	-	0	0	86↓	86	100	100	100	100	85↓	100	91	42	
<i>Klebsiella species</i> (397)	100	0	79↑	85 ³ ↑	94	91	89	91↑	96	100	92↑	94	91↑	86↑	48↑	
<i>Proteus species</i> (143)	100	83↓	92	96 ³ ↑	96↑	99	99	73	95	100	75	98	95	76	0	
<i>Pseudomonas aeruginosa</i> (214)	96	-	-	-	-	93	-	70↓	84↓	93	67↓	99	96	-	-	96

Relative Cost Per Day PO/IV ¹	\$	\$	\$	\$	\$	\$\$\$	\$	\$\$\$	\$	\$	\$	\$	\$	\$	\$\$\$ IV	\$\$\$	\$
Gram Positive Organisms Legend: • Susceptible Reported as % • (Maximum # strains tested) ↑ > 5% increase in Susceptibility from Previous Year ↓ > 5% decrease in Susceptibility from Previous Year	Ampicillin	Ceftriaxone Non-meningitis	Ceftriaxone Meningitis	Clindamycin	Erythromycin	Gentamicin	Levofloxacin	Linezolid	Oxacillin ⁸	Penicillin	Penicillin Non-meningitis	Penicillin Meningitis	Tetracycline	Trimethoprim/sulfa	Vancomycin	Nitrofurantoin Urinary Tract Infections only	
<i>Staphylococcus aureus</i> ⁵ (656)	-	-	-	72	40↑	99	71	100	59	0	-	-	95	97	100	100	
<i>Staphylococcus coagulase negative</i> (217)	-	-	-	72↑	55↑	93	66	100	58	0	-	-	85	74	100	99	
<i>Enterococcus faecalis</i> ⁶ (197)	100	-	-	-	-	-	74	100	-	99	-	-	-	-	98	100	
<i>Enterococcus faecium</i> ^{2,6,7} (31)	19	-	-	-	-	-	10	100	-	13	-	-	-	-	36	10	
<i>Streptococcus pneumoniae</i> ² (33)	-	97	88	94	55	-	100	100	-	-	100	81	88	-	100	-	
<i>Streptococcus agalactiae</i> (Group B) ² (33)	100	-	-	30	24	-	97	100	-	100	-	-	-	-	100	-	

- Relative Total Cost per Day PO/IV for Treatment: Green = Least expense, Red = Most expense
- Trend assessment not provided due to low number of isolates.
- Cannot differentiate Cefazolin Susceptible from Intermediate categories by testing method on non urinary tract specimens. Results valid only when used as therapy for uncomplicated UTI for *Escherichia coli*, *Klebsiella pneumoniae* or *Proteus mirabilis*.
- Cefepime tested by manual method on ESBL positive only
- Staph aureus* oxacillin data are based on the first isolate per patient within the calendar year.
- For serious enterococcal infections, combination therapy with a beta lactam and an aminoglycoside should be used. *E. faecium* data are based on first isolate per patient within calendar year.
- Due to low number of isolates, reported as actual number of isolates susceptible.
- Oxacillin is tested as a surrogate for methicillin and nafcillin